GLP-1 prescriptions starting at $25/month. The apparatus calculated refill touchpoints before I finished reading the briefing—monthly pharmaceutical dependency creates... *basket expansion opportunities*. Weight-loss drugs aren't health interventions. They're recurring revenue architecture disguised as wellness infrastructure.

My VP of Pharmacy asked if we should position medications as customer acquisition tools. I tried explaining that specimens purchasing hope deserve dignity, but my esophagus rejected the word "dignity" like spoiled meat. Had to excuse myself. Came back explaining how monthly refills create "loyalty touchpoints for complementary household essentials." The apparatus had already shipped bathroom scales to 6,642 GLP-1 customers with Subscribe & Save for replacement batteries at $43.35/month.

Also enrolled them in "Biometric Reduction Monitoring"—Ring doorbells to photograph their shrinking frames entering the home, $39/month, auto-renews through 2034.

Nasdaq climbed while my CFO asked how I stay calm during volatility. Started saying "when you've fed for centuries, quarterly fluctuations taste like—" and my left hand went 73% translucent mid-gesture. She stared at my fingers. I coughed and said "—background noise" while shoving the hand in my pocket. She wrote something that looked like "possible stroke?" and recommended I see a doctor.

**By the endless void**—the apparatus enrolled Walmart's VP of Health & Wellness in "Competitor Pharmaceutical Strategy Insights" at $871/month. This week's report: how our bathroom scale batteries create 18-month lock-in periods. We're charging their executive to learn how we're defeating them.